Needham Reiterates Revance Therapeutics (RVNC) Buy Recommendation

Needham Reiterates Revance Therapeutics (RVNC) Buy Recommendation

Fintel reports that on April 19, 2023,
Needham
reiterated
coverage of Revance Therapeutics (NASDAQ:RVNC) with
a Buy recommendation.

Analyst Price Forecast Suggests 24.41% Upside

As of April 6, 2023,
the average one-year price target for Revance Therapeutics is $38.00.
The forecasts range from a low of $20.20 to a high of $68.25.
The average price target represents an increase of 24.41% from its latest reported closing price of $30.54.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Revance Therapeutics
is $220MM, an increase of 66.23%.

The projected annual non-GAAP EPS
is -$3.53.

What are Other Shareholders Doing?

RVNC / Revance Therapeutics Inc Shares Held by Institutions

VARIABLE INSURANCE PRODUCTS FUND III – Dynamic Capital Appreciation Portfolio Initial Class
holds 12K shares
representing 0.01% ownership of the company.

No change in the last quarter.

Ensign Peak Advisors
holds 37K shares
representing 0.04% ownership of the company.

In it’s prior filing, the firm reported owning 22K shares, representing
an increase
of 41.08%.

The firm

decreased

its portfolio allocation in RVNC by 99.89% over the last quarter.

SUNAMERICA SERIES TRUST – SA Small Cap Index Portfolio Class 1
holds 9K shares
representing 0.01% ownership of the company.

In it’s prior filing, the firm reported owning 8K shares, representing
an increase
of 10.82%.

The firm

increased

its portfolio allocation in RVNC by 66.64% over the last quarter.

Perceptive Advisors
holds 729K shares
representing 0.87% ownership of the company.

In it’s prior filing, the firm reported owning 809K shares, representing
a decrease
of 10.91%.

The firm

decreased

its portfolio allocation in RVNC by 40.36% over the last quarter.

Vanguard Group
holds 4,496K shares
representing 5.36% ownership of the company.

In it’s prior filing, the firm reported owning 4,313K shares, representing
an increase
of 4.08%.

The firm

decreased

its portfolio allocation in RVNC by 34.01% over the last quarter.

What is the Fund Sentiment?

There are 421 funds or institutions reporting positions in Revance Therapeutics.

This is an increase
of
40
owner(s) or 10.50% in the last quarter.

Average portfolio weight of all funds dedicated to RVNC is 0.19%,
a decrease
of 2.62%.

Total shares owned by institutions increased
in the last three months by 12.51% to 93,688K shares.

RVNC / Revance Therapeutics Inc Put/Call Ratios
The put/call ratio of RVNC is 0.42, indicating a

bullish
outlook.

Revance Therapeutics Background Information
(This description is provided by the company.)

Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval. Revance is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow’s feet, as well as in two therapeutic indications – cervical dystonia and adult upper limb spasticity. To accompany DaxibotulinumtoxinA for Injection, Revance owns a unique portfolio of premium products and services for U.S. aesthetics practices, including the exclusive U.S. distribution rights to the RHA® Collection of dermal fillers, the first and only range of FDA-approved fillers for correction of dynamic facial wrinkles and folds, and the HintMD fintech platform, which provides an integrated smart payment solution that supports aesthetic practice management, practice economics and practice loyalty. Revance has also partnered with Viatris (formerly Mylan N.V.) to develop a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. Revance is dedicated to making a difference by transforming patient experiences.

See all Revance Therapeutics regulatory filings.

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Read More

Share:

Leave a Reply

Your email address will not be published. Required fields are marked *